# A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients

> **NCT07185880** · PHASE1,PHASE2 · RECRUITING · sponsor: **Myosin Therapeutics Inc.** · enrollment: 36 (estimated)

## Conditions studied

- Glioblastoma (GBM)

## Interventions

- **DRUG:** MT-125

## Key facts

- **NCT ID:** NCT07185880
- **Lead sponsor:** Myosin Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2026-10-31
- **Final completion:** 2032-02
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07185880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07185880, "A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07185880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*